Clinical Trials Logo
  1. Home
  2. Severe Combined Immunodeficiency
  3. NCT04246840
  4. Details
NCT04246840 Clinical Trial

Study Through Imaging of Visceral Lymphoid Organs in Patients With SCID Who Have Recieved Bone Marrow Allograft

Severe Combined Immunodeficiency Clinical Trial

— LymphImaging  

Official title:
Study Through Imaging of Mediastinal and Abdominopelvic Secondary Lymphoid Organs (Lymph Nodes) in Patients With Severe Combined Immunodeficiencies (SCID) Who Have Recieved Bone Narrow Allograft

Clinical Trial Details — Status: Completed

Administrative data
NCT number NCT04246840
Other study ID # AARIP-01
Secondary ID
Status Completed
Phase
First received
Last updated
Start date January 13, 2020
Est. completion date February 15, 2021

Study information
Verified date July 2021
Source Association Pour l'Aide a la Recherche en Immunologie Pediatrique
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

To investigate the presence of seconday of lymphoid organs in patients who underwent allogenic hematopoietic stem cell transplantation 15 to 45 years ago. The goal aims to assess the development of seconday lymphoid organs given the fact that the absence of myeloablation these patients present a split chimerism between T lymphocytes and the other leucocytes. Thus, they may not be able to generate seconday lymphoid organs. Practically, whole body MRI is being used to visualise and quantify both mediastinal and intraabdominal lymph nodes. Delta will be compared with those obtained in healthy age-matched individuals. It is scheduled to include 15 patients and 15 controls.

Recruitment information / eligibility
Status Completed
Enrollment 18
Est. completion date February 15, 2021
Est. primary completion date February 15, 2021
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Patients with SCID transplanted 15-45 years ago Exclusion Criteria: - None

Study Design

Related Conditions & MeSH terms

Locations
Country Name City State
France Hôpital Necker Paris

Sponsors (1)
Lead Sponsor Collaborator
Association Pour l'Aide a la Recherche en Immunologie Pediatrique

Country where clinical trial is conducted

France, 

Outcome
Type Measure Description Time frame Safety issue
Primary Size of mediastinal and intraabdominal lymph nodes analysis by MRI 1 year
See also
  Status Clinical Trial Phase
Completed NCT00006335 - Influences on Female Adolescents' Decisions Regarding Testing for Carrier Status of XSCID N/A
Not yet recruiting NCT02231983 - Clinical Characteristics and Genetic Profiles of Severe Combined Immunodeficiency in China N/A
Active, not recruiting NCT03597594 - Haplocompatible Transplant Using TCRα/β Depletion Followed by CD45RA-Depleted Donor Lymphocyte Infusions for Severe Combined Immunodeficiency (SCID) Phase 1/Phase 2
Completed NCT00000603 - Cord Blood Stem Cell Transplantation Study (COBLT) Phase 2
Completed NCT00001255 - Gene Transfer Therapy for Severe Combined Immunodeficieny Disease (SCID) Due to Adenosine Deaminase (ADA) Deficiency: A Natural History Study N/A
Recruiting NCT05651113 - The Experience of Screening for SCID
Completed NCT00794508 - MND-ADA Transduction of CD34+ Cells From Children With ADA-SCID Phase 2
Recruiting NCT03538899 - Autologous Gene Therapy for Artemis-Deficient SCID Phase 1/Phase 2
Recruiting NCT05298930 - Feasibility Study to Assess an Adapted Physical Activity Program in Children, Adolescents and Young Adults Requiring Hematopoietic Stem Cell Transplantation N/A
Recruiting NCT01821781 - Immune Disorder HSCT Protocol Phase 2
Completed NCT00845416 - Newborn Screening for Severe Combined Immunodeficiency (SCID) in a High-Risk Population N/A
Terminated NCT00006054 - Allogeneic Bone Marrow Transplantation in Patients With Primary Immunodeficiencies N/A
Completed NCT03878069 - Registry Study of Revcovi Treatment in Patients With ADA-SCID
Recruiting NCT01019876 - Risk-Adapted Allogeneic Stem Cell Transplantation For Mixed Donor Chimerism In Patients With Non-Malignant Diseases Phase 2/Phase 3
Completed NCT03513328 - Conditioning Regimen for Allogeneic Hematopoietic Stem-Cell Transplantation Phase 1/Phase 2
Withdrawn NCT02177760 - Sirolimus Prophylaxis for aGVHD in TME SCID Phase 2
Recruiting NCT00695279 - Long Term Follow Up Of Patients Who Have Received Gene Therapy Or Gene Marked Products
Completed NCT01420627 - EZN-2279 in Patients With ADA-SCID Phase 3
Terminated NCT02127892 - SCID Bu/Flu/ATG Study With T Cell Depletion Phase 1/Phase 2
Completed NCT01529827 - Fludarabine Phosphate, Melphalan, and Low-Dose Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies Phase 2